We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Feb 2023 - 09 Feb 2023

Rapid POC Diagnostic Assay Could Detect and Measure Fentanyl Neutralizing Antibodies

By LabMedica International staff writers
Posted on 23 Jan 2023
Print article
Image: The new test is designed to measure neutralizing antibodies of the deadly opioid fentanyl (Photo courtesy of AXIM)
Image: The new test is designed to measure neutralizing antibodies of the deadly opioid fentanyl (Photo courtesy of AXIM)

Fentanyl is a powerful synthetic opioid with a strong addiction profile that is 50 to 100 times stronger than morphine and is the world’s leading cause of overdose. The current healthcare landscape makes it difficult to prevent fentanyl addiction and overdose. Researchers continue to conduct new studies on potential immunotherapies and vaccines that can prevent fentanyl from crossing the blood-brain barrier to preemptively circumvent its overdose effects. Recent studies indicate that fentanyl neutralizing antibodies could prevent overdose deaths, although scientists will need to quantitatively measure a patient’s neutralizing antibodies throughout clinical studies and for relapse prevention from boosters. Such a test currently does not exist on the market.

AXIM Biotechnologies, Inc. (San Diego, CA, USA) is leveraging its experience in diagnostics and working with neutralizing antibodies to develop a rapid point-of-care diagnostic assay that will detect and measure the levels of fentanyl neutralizing antibodies. The breakthrough diagnostic solution will allow therapeutic and vaccine scientists to bring their research from the lab to the clinic more quickly, thanks to the fast time to result in clinical settings provided by AXIM’s new test. The US and other government and regulatory bodies are incentivizing organizations through grants and licenses to conduct research on potential therapeutics or vaccines that can prevent fentanyl overdose or addiction. AXIM will market its newly-developed test to these research institutions as a reliable way to measure neutralizing antibodies in clinical trial patients.

AXIM has filed a provisional patent application with the U.S. Patent and Trademark Office on its innovative new test. Additionally, the company has filed for a license to handle the controlled substance with the Drug Enforcement Administration (DEA) as required for research. AXIM’s ongoing discussions with various academic and research groups on potential collaboration on the new test has generated broad enthusiasm among the scientific community for its development and commercialization.

“This test is another example of the broad applications of AXIM’s diagnostic platform,” said John Huemoeller II, CEO of AXIM Biotechnologies. “We continue to be able to leverage our processes and scientific expertise in developing rapid diagnostic assays of commercial significance. As most know, the fentanyl crisis continues to plague the US as well as many other countries and scientists from a myriad of fields continue to research ways to combat the devastation this lethal drug is causing. The commercial applications of this test are far and wide and represent a massive opportunity for AXIM. Once we receive our DEA license, we plan to begin clinical studies on the assay immediately, with the hopes of commercialization in the second quarter of 2023.”

Related Links:
AXIM Biotechnologies, Inc.

Gold Supplier
Zika Virus Anitobody Test
Zika Virus IgM μ-capture
New
Electronic Pipette
BenchMate Electronic (OBE) Pipette
New
PT/INR Monitoring System
Coag-Sense PT2
New
Silver Supplier
Four-Channel Laboratory Alarm Timer
Laboratory Timer

Print article
MEDLAB - INFORMA

Channels

Immunology

view channel
Image: Histopathology of Langerhans cell histiocytosis: The variation in nuclear contours of these cells is evident in this lesion. Classic `kidney bean` nuclei of Langerhans cells with a central groove are present (Photo courtesy of John Lazarchick, MD)

Cooperativity Between Myeloid Lineages Promotes Langerhans Cell Histiocytosis Pathology

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia seen in children and adults who present with lesions composed of pathologic variants of myeloid cells that share certain phenotypic... Read more

Microbiology

view channel
Image: Medical illustration of Carbapenem-resistant Enterobacteriacea (Photo courtesy of CDC, Stephanie Rossow)

Breakthrough Test Enables Targeted Antibiotic Therapy for Various Enterobacter Species

Bacteria of the Enterobacter genus are considered to be the most dangerous bacteria linked to hospital infections across the world. Some of their representatives demonstrate high resistance to commonly-used... Read more

Technology

view channel
Image: Flexible copper sensor made cheaply from ordinary materials (Photo courtesy of University of São Paulo)

Low-Cost Portable Sensor Detects Heavy Metals in Sweat

Heavy metals like lead and cadmium can be found in batteries, cosmetics, food and many other things that have become a part of daily life. However, they become toxic if they accumulate in the human body... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.